Novel molecular targets in the treatment of cardiac hypertrophy

Recent Advances in Cardiovascular Drug Discovery

Volumn 1, Issue 1, 2006, Pages 1-20

  Luedde, Mark ^a   Katus, Hugo A ^a   Frey, Norbert ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Akt; Calcineurin; Cyclic GMP PKG 1; Gq G11; Glycogen synthase kinase 3; GP130; Histone deacetylases; Hypertrophy; MAPK; Myocyte enhancer factor 2; Na H exchanger; Phosphoinositide 3 kinase; Small G proteins

Indexed keywords

CALCINEURIN; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; DSCR1 PROTEIN, HUMAN; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; HISTONE DEACETYLASE; MUSCLE PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; SIGNAL PEPTIDE; STAT3 PROTEIN; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG;

ANIMAL; CARDIOMEGALY; HUMAN; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; CALCINEURIN; CARDIOMEGALY; CYCLIC GMP; CYCLIC GMP-DEPENDENT PROTEIN KINASES; GLYCOGEN SYNTHASE KINASE 3; HISTONE DEACETYLASES; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MAP KINASE SIGNALING SYSTEM; MUSCLE PROTEINS; NFATC TRANSCRIPTION FACTORS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 85047287554     PISSN: 15748901     EISSN: 22123962     Source Type: Journal    
DOI: 10.2174/157489006775244290     Document Type: Article

References (275)

1. Berenji K, Drazner MH, Rothermel BA, Hill JA. Does loadinduced ventricular hypertrophy progress to systolic heart failure? Am J Physiol Heart Circ Physiol 2005; 289: H8-H16.
2. Frey N, Katus HA, Olson EN, Hill JA. Hypertrophy of the heart: a new therapeutic target? Circulation 2004; 109: 1580-1589.
3. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561-1566.
4. Lorell BH, Carabello BA. Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation 2000; 102: 470-479.
5. Gardin JM, Brunner D, Schreiner PJ, et al. Demographics and correlates of five-year change in echocardiographic left ventricular mass in young black and white adult men and women: the Coronary Artery Risk Development in Young Adults (CARDIA) study. J Am Coll Cardiol 2002; 40: 529-535.
6. Mathew J, Sleight P, Lonn E, et al. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 2001; 104: 1615-1621.
7. Okin PM, Roman MJ, Lee ET, Galloway JM, Howard BV, Devereux RB. Combined echocardiographic left ventricular hypertrophy and electrocardiographic ST depression improve prediction of mortality in American Indians: the Strong Heart Study. Hypertension 2004; 43: 769-774.
8. Devereux RB, Wachtell K, Gerdts E, et al. Prognostic significance of left ventricular mass change during treatment of hypertension. Jama 2004; 292: 2350-2356.
9. Frey N, Olson EN. Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 2003; 65: 45-79.
10. MacLellan WR, Schneider MD. Genetic dissection of cardiac growth control pathways. Annu Rev Physiol 2000; 62: 289-319.
11. Molkentin JD, Dorn IG, 2nd. Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu Rev Physiol 2001; 63: 391-426.
12. Clf Medical Technology Acceleration Program, Inc.: WO03006619A3 (2003).
13. Voelkel, H.: US6875581 (2005).
14. Arai, K.I., Liu, J.: US6780597 (2004).
15. Eric, N.O., Stephen, R.G., Jeffrey, D.M.: AU074834B2 (2002).
16. Matsui, H., Matsushita, M.: EP146507 (2004).
17. Klee CB, Ren H, Wang X. Regulation of the calmodulinstimulated protein phosphatase, calcineurin. J Biol Chem 1998; 273: 13367-13370.
18. Crabtree GR, Olson EN. NFAT signaling: choreographing the social lives of cells. Cell 2002; 109 Suppl: S67-79.
19. Molkentin JD, Lu JR, Antos CL, et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998; 93: 215-228.
20. Leinwand LA. Calcineurin inhibition and cardiac hypertrophy: a matter of balance. Proc Natl Acad Sci USA 2001; 98: 2947-2949.
21. Sussman MA, Lim HW, Gude N, et al. Prevention of cardiac hypertrophy in mice by calcineurin inhibition. Science 1998; 281: 1690-1693.
22. Meguro T, Hong C, Asai K, et al. Cyclosporine attenuates pressure-overload hypertrophy in mice while enhancing susceptibility to decompensation and heart failure. Circ Res 1999; 84: 735-740.
23. Shimoyama M, Hayashi D, Takimoto E, et al. Calcineurin plays a critical role in pressure overload-induced cardiac hypertrophy. Circulation 1999; 100: 2449-2454.
24. Mervaala E, Muller DN, Park JK, et al. Cyclosporin A protects against angiotensin II-induced end-organ damage in double transgenic rats harboring human renin and angiotensinogen genes. Hypertension 2000; 35: 360-366.
25. Zhang W, Kowal RC, Rusnak F, Sikkink RA, Olson EN, Victor RG. Failure of calcineurin inhibitors to prevent pressure-overload left ventricular hypertrophy in rats. Circ Res 1999; 84: 722-728.
26. Ding B, Price RL, Borg TK, Weinberg EO, Halloran PF, Lorell BH. Pressure overload induces severe hypertrophy in mice treated with cyclosporine, an inhibitor of calcineurin. Circ Res 1999; 84: 729-734.
27. Ventura HO, Malik FS, Mehra MR, Stapleton DD, Smart FW. Mechanisms of hypertension in cardiac transplantation and the role of cyclosporine. Curr Opin Cardiol 1997; 12: 375-381.
28. Olson EN, Williams RS. Calcineurin signaling and muscle remodeling. Cell 2000; 101: 689-692.
29. Hill JA, Karimi M, Kutschke W, et al. Cardiac hypertrophy is not a required compensatory response to short-term pressure overload. Circulation 2000; 101: 2863-2869.
30. Rothermel BA, McKinsey TA, Vega RB, et al. Myocyte-enriched calcineurin-interacting protein, MCIP1, inhibits cardiac hypertrophy in vivo. Proc Natl Acad Sci USA 2001; 98: 3328-3333.
31. Scott, J.D., Coghlan, V.M., Howard, M., Gallantin, W.M.: US5807693 (1998).
32. Coghlan VM, Perrino BA, Howard M, et al. Association of protein kinase A and protein phosphatase 2B with a common anchoring protein. Science 1995; 267: 108-111.
33. Taigen T, De Windt LJ, Lim HW, Molkentin JD. Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy. Proc Natl Acad Sci USA 2000; 97: 1196-1201.
34. Sun L, Youn HD, Loh C, Stolow M, He W, Liu JO. Cabin 1, a negative regulator for calcineurin signaling in T lymphocytes. Immunity 1998; 8: 703-711.
35. Lai MM, Burnett PE, Wolosker H, Blackshaw S, Snyder SH. Cain, a novel physiologic protein inhibitor of calcineurin. J Biol Chem 1998; 273: 18325-18331.
36. De Windt LJ, Lim HW, Bueno OF, et al. Targeted inhibition of calcineurin attenuates cardiac hypertrophy in vivo. Proc Natl Acad Sci USA 2001; 98: 3322-3327.
37. Lin X, Sikkink RA, Rusnak F, Barber DL. Inhibition of calcineurin phosphatase activity by a calcineurin B homologous protein. J Biol Chem 1999; 274: 36125-36131.
38. Fuentes JJ, Pritchard MA, Planas AM, Bosch A, Ferrer I, Estivill X. A new human gene from the Down syndrome critical region encodes a proline-rich protein highly expressed in fetal brain and heart. Hum Mol Genet 1995; 4: 1935-1944.
39. Rothermel B, Vega RB, Yang J, Wu H, Bassel-Duby R, Williams RS. A protein encoded within the Down syndrome critical region is enriched in striated muscles and inhibits calcineurin signaling. J Biol Chem 2000; 275: 8719-8725.
40. Kingsbury TJ, Cunningham KW. A conserved family of calcineurin regulators. Genes Dev 2000; 14: 1595-1604.
41. Yang J, Rothermel B, Vega RB, et al. Independent signals control expression of the calcineurin inhibitory proteins MCIP1 and MCIP2 in striated muscles. Circ Res 2000; 87: E61-68.
42. Hill JA, Rothermel B, Yoo KD, et al. Targeted inhibition of calcineurin in pressure-overload cardiac hypertrophy. Preservation of systolic function. J Biol Chem 2002; 277: 10251-10255.
43. Pedram A, Razandi M, Aitkenhead M, Levin ER. Estrogen inhibits cardiomyocyte hypertrophy in vitro: Antagonism of calcineurin-related hypertrophy through induction of MCIP1. J Biol Chem 2005.
44. Vega RB, Rothermel BA, Weinheimer CJ, et al. Dual roles of modulatory calcineurin-interacting protein 1 in cardiac hypertrophy. Proc Natl Acad Sci USA 2003; 100: 669-674.
45. Sanna B, Kaiser RA, Molkentin J: Analysis of MCIP1 and MCIP2 Null Mice Suggests That MCIP Functions as an Enhancer of Calcineurin Signaling In Vivo: 2nd Annual Symposium of the American Heart Association Council on Basic Cardiovascular Sciences. Keystone, CO, Circ Res 2005, vol 97, e25.
46. Hilioti Z, Gallagher DA, Low-Nam ST, et al. GSK-3 kinases enhance calcineurin signaling by phosphorylation of RCNs. Genes Dev 2004; 18: 35-47.
47. Olson, E.N., Frey, N.: US20040186275A1 (2004).
48. Frey N, Richardson JA, Olson EN. Calsarcins, a novel family of sarcomeric calcineurin-binding proteins. Proc Natl Acad Sci USA 2000; 97: 14632-14637.
49. Frey N, Olson EN. Calsarcin-3, a novel skeletal muscle-specific member of the calsarcin family, interacts with multiple Z-disc proteins. J Biol Chem 2002; 277: 13998-14004.
50. Faulkner G, Pallavicini A, Comelli A, et al. FATZ, a filamin-, actinin-, and telethonin-binding protein of the Z-disc of skeletal muscle. J Biol Chem 2000; 275: 41234-41242.
51. Takada F, Vander Woude DL, Tong HQ, et al. Myozenin: an alpha-actinin-and gamma-filamin-binding protein of skeletal muscle Z lines. Proc Natl Acad Sci USA 2001; 98: 1595-1600.
52. Knoll R, Hoshijima M, Hoffman HM, et al. The cardiac mechanical stretch sensor machinery involves a Z disc complex that is defective in a subset of human dilated cardiomyopathy. Cell 2002; 111: 943-955.
53. Frey N, Barrientos T, Shelton JM, et al. Mice lacking calsarcin-1 are sensitized to calcineurin signaling and show accelerated cardiomyopathy in response to pathological biomechanical stress. Nat Med 2004; 10: 1336-1343.
54. Arber S, Caroni P. Specificity of single LIM motifs in targeting and LIM/LIM interactions in situ. Genes Dev 1996; 10: 289-300.
55. Heineke J, Kempf T, Kraft T, et al. Downregulation of cytoskeletal muscle LIM protein by nitric oxide: impact on cardiac myocyte hypertrophy. Circulation 2003; 107: 1424-1432.
56. Heineke J, Ruetten H, Willenbockel C, et al. Attenuation of cardiac remodeling after myocardial infarction by muscle LIM protein-calcineurin signaling at the sarcomeric Z-disc. Proc Natl Acad Sci USA 2005; 102: 1655-1660.
57. Li HH, Kedar V, Zhang C, et al. Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex. J Clin Invest 2004; 114sb: 1058-1071.
58. Bodine SC, Latres E, Baumhueter S, et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001; 294: 1704-1708.
59. Gomes MD, Lecker SH, Jagoe RT, Navon A, Goldberg AL. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci USA 2001; 98: 14440-14445.
60. Zou Y, Hiroi Y, Uozumi H, et al. Calcineurin plays a critical role in the development of pressure overload-induced cardiac hypertrophy. Circulation 2001; 104: 97-101.
61. Bueno OF, Brandt EB, Rothenberg ME, Molkentin JD. Defective T cell development and function in calcineurin A beta-deficient mice. Proc Natl Acad Sci USA 2002; 99: 9398-9403.
62. Bueno OF, Wilkins BJ, Tymitz KM, et al. Impaired cardiac hypertrophic response in Calcineurin Abeta-deficient mice. Proc Natl Acad Sci USA 2002; 99: 4586-4591.
63. Takimoto E, Champion HC, Belardi D, et al. cGMP catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism. Circ Res 2005; 96: 100-109.
64. 2+-calcineurin-NFAT cascade in cardiac myocytes. Cardiovasc Res 2004; 63: 450-457.
65. Braz JC, Bueno OF, Liang Q, et al. Targeted inhibition of p38 MAPK promotes hypertrophic cardiomyopathy through upregulation of calcineurin-NFAT signaling. J Clin Invest 2003; 111: 1475-1486.
66. De Windt LJ, Lim HW, Haq S, Force T, Molkentin JD. Calcineurin promotes protein kinase C and c-Jun NH2-terminal kinase activation in the heart. Cross-talk between cardiac hypertrophic signaling pathways. J Biol Chem 2000; 275: 13571-13579.
67. Wilkins BJ, Dai YS, Bueno OF, et al. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ Res 2004; 94: 110-118.
68. Burkard N, Becher J, Heindl C, Neyses L, Schuh K, Ritter O. Targeted proteolysis sustains calcineurin activation. Circulation 2005; 111: 1045-1053.
69. van Rooij E, Doevendans PA, Crijns HJ, et al. MCIP1 overexpression suppresses left ventricular remodeling and sustains cardiac function after myocardial infarction. Circ Res 2004; 94: e18-26.
70. Aramburu J, Yaffe MB, Lopez-Rodriguez C, Cantley LC, Hogan PG, Rao A. Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A. Science 1999; 285: 2129-2133.
71. Pu WT, Ma Q, Izumo S. NFAT transcription factors are critical survival factors that inhibit cardiomyocyte apoptosis during phenylephrine stimulation in vitro. Circ Res 2003; 92: 725-731.
72. Roehrl MH, Kang S, Aramburu J, Wagner G, Rao A, Hogan PG. Selective inhibition of calcineurin-NFAT signaling by blocking protein-protein interaction with small organic molecules. Proc Natl Acad Sci USA 2004; 101: 7554-7559.
73. Bush E, Fielitz J, Melvin L, et al. A small molecular activator of cardiac hypertrophy uncovered in a chemical screen for modifiers of the calcineurin signaling pathway. Proc Natl Acad Sci USA 2004; 101: 2870-2875.
74. Mendelsohn ME. Viagra: now mending hearts. Nat Med 2005; 11: 115-116.
75. Horio T, Nishikimi T, Yoshihara F, Matsuo H, Takishita S, Kangawa K. Inhibitory regulation of hypertrophy by endogenous atrial natriuretic peptide in cultured cardiac myocytes. Hypertension 2000; 35: 19-24.
76. Holtwick R, van Eickels M, Skryabin BV, et al. Pressureindependent cardiac hypertrophy in mice with cardiomyocyterestricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A. J Clin Invest 2003; 111: 1399-1407.
77. Calderone A, Thaik CM, Takahashi N, Chang DL, Colucci WS. Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J Clin Invest 1998; 101: 812-818.
78. Ichinose F, Bloch KD, Wu JC, et al. Pressure overload-induced LV hypertrophy and dysfunction in mice are exacerbated by congenital NOS3 deficiency. Am J Physiol Heart Circ Physiol 2004; 286: H1070-1075.
79. Wollert KC, Fiedler B, Gambaryan S, et al. Gene transfer of cGMP-dependent protein kinase I enhances the antihypertrophic effects of nitric oxide in cardiomyocytes. Hypertension 2002; 39: 87-92.
80. Feil R, Lohmann SM, de Jonge H, Walter U, Hofmann F. Cyclic GMP-dependent protein kinases and the cardiovascular system: insights from genetically modified mice. Circ Res 2003; 93: 907-916.
81. Fiedler B, Lohmann SM, Smolenski A, et al. Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes. Proc Natl Acad Sci USA 2002; 99: 11363-11368.
82. Tang KM, Wang GR, Lu P, et al. Regulator of G-protein signaling-2 mediates vascular smooth muscle relaxation and blood pressure. Nat Med 2003; 9: 1506-1512.
83. Takimoto E, Champion HC, Li M, et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 2005; 11: 214-222.
84. Gonzales-Cadavid, N.F., Rajfer, J.: US20050085486A1 (2005).
85. Gonzales-Cadavid, N.F., Rajfer, J.: WO04037183A3 (2004).
86. Niazi, S.: US6338862 (2002).
87. Orme, M., Sawyer, J.: WO0200658 (2002).
88. Orme, M.W., Sawyer, J.S.: US6825197 (2004).
89. Lu, Y.F., Antczak, C., Oudenes, J., Tao, Y.: US6204383 (2001).
90. Champion HC, Moslehi J, Hemnes A, Mahmud M, Takimoto E, Kass DA: Sildenafil inhibits cardiac hypertrophy in vivo: Role of the Rhoa/rho kinase pathway: 2nd annual symposium of the american heart association council on basic cardiovascular sciences. keystone, CO, Circ Res, 2005, 97, e9.
91. Dorn GW, 2nd, Force T. Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest 2005; 115: 527-537.
92. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002; 296: 1655-1657.
93. Schluter KD, Goldberg Y, Taimor G, Schafer M, Piper HM. Role of phosphatidylinositol 3-kinase activation in the hypertrophic growth of adult ventricular cardiomyocytes. Cardiovasc Res 1998; 40: 174-181.
94. Chesley A, Lundberg MS, Asai T, et al. The beta(2)-adrenergic receptor delivers an antiapoptotic signal to cardiac myocytes through G(i)-dependent coupling to phosphatidylinositol 3'-kinase. Circ Res 2000; 87: 1172-1179.
95. Zhu WZ, Zheng M, Koch WJ, Lefkowitz RJ, Kobilka BK, Xiao RP. Dual modulation of cell survival and cell death by beta(2)-adrenergic signaling in adult mouse cardiac myocytes. Proc Natl Acad Sci USA 2001; 98: 1607-1612.
96. Shioi T, Kang PM, Douglas PS, et al. The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J 2000; 19: 2537-2548.
97. McMullen JR, Shioi T, Zhang L, et al. Phosphoinositide 3-kinase(p110alpha) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc Natl Acad Sci USA 2003; 100: 12355-12360.
98. Oudit GY, Crackower MA, Eriksson U, et al. Phosphoinositide 3-kinase gamma-deficient mice are protected from isoproterenolinduced heart failure. Circulation 2003; 108: 2147-2152.
99. Monia, B.P., Cowsert, L.M.: US6020199 (2000).
100. Monia, B.P., Cowsert, L.M., McKay, R.: US6284538 (2001).
101. Crackower MA, Oudit GY, Kozieradzki I, et al. Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell 2002; 110: 737-749.
102. Latronico MV, Costinean S, Lavitrano ML, Peschle C, Condorelli G. Regulation of cell size and contractile function by AKT in cardiomyocytes. Ann N Y Acad Sci 2004; 1015: 250-260.
103. Matsui T, Rosenzweig A. Convergent signal transduction pathways controlling cardiomyocyte survival and function: the role of PI 3-kinase and Akt. J Mol Cell Cardiol 2005; 38: 63-71.
104. Shioi T, McMullen JR, Kang PM, et al. Akt/protein kinase B promotes organ growth in transgenic mice. Mol Cell Biol 2002; 22: 2799-2809.
105. Condorelli G, Drusco A, Stassi G, et al. Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice. Proc Natl Acad Sci USA 2002; 99: 12333-12338.
106. Matsui T, Li L, Wu JC, et al. Phenotypic spectrum caused by transgenic overexpression of activated Akt in the heart. J Biol Chem 2002; 277: 22896-22901.
107. Shiojima I, Sato K, Izumiya Y, et al. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest 2005; 115: 2108-2118.
108. Eldar-Finkelman, H.: US6780625 (2004).
109. Nuss, J.M., Harrison, S.D., Ring, D.B., et al.: US6489344 (2002).
110. Brown EJ, Beal PA, Keith CT, Chen J, Shin TB, Schreiber SL. Control of p70 s6 kinase by kinase activity of FRAP in vivo. Nature 1995; 377: 441-446.
111. McManus EJ, Alessi DR. TSC1-TSC2: a complex tale of PKBmediated S6K regulation. Nat Cell Biol 2002; 4: E214-216.
112. Tee AR, Fingar DC, Manning BD, Kwiatkowski DJ, Cantley LC, Blenis J. Tuberous sclerosis complex-1 and-2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci USA 2002; 99: 13571-13576.
113. Potter CJ, Pedraza LG, Huang H, Xu T. The tuberous sclerosis complex (TSC) pathway and mechanism of size control. Biochem Soc Trans 2003; 31: 584-586.
114. McMullen JR, Sherwood MC, Tarnavski O, et al. Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation 2004; 109: 3050-3055.
115. Proud CG. Ras, PI3-kinase and mTOR signaling in cardiac hypertrophy. Cardiovasc Res 2004; 63: 403-413.
116. Boluyt MO, Zheng JS, Younes A, et al. Rapamycin inhibits alpha 1-adrenergic receptor-stimulated cardiac myocyte hypertrophy but not activation of hypertrophy-associated genes. Evidence for involvement of p70 S6 kinase. Circ Res 1997; 81: 176-186.
117. Sadoshima J, Izumo S. Rapamycin selectively inhibits angiotensin II-induced increase in protein synthesis in cardiac myocytes in vitro. Potential role of 70-kD S6 kinase in angiotensin II-induced cardiac hypertrophy. Circ Res 1995; 77: 1040-1052.
118. Shioi T, McMullen JR, Tarnavski O, et al. Rapamycin attenuates load-induced cardiac hypertrophy in mice. Circulation 2003; 107: 1664-1670.
119. Morisco C, Zebrowski D, Condorelli G, Tsichlis P, Vatner SF, Sadoshima J. The Akt-glycogen synthase kinase 3beta pathway regulates transcription of atrial natriuretic factor induced by betaadrenergic receptor stimulation in cardiac myocytes. J Biol Chem 2000; 275: 14466-14475.
120. Antos CL, McKinsey TA, Frey N, et al. Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo. Proc Natl Acad Sci USA 2002; 99: 907-912.
121. Badorff C, Ruetten H, Mueller S, et al. Fas receptor signaling inhibits glycogen synthase kinase 3 beta and induces cardiac hypertrophy following pressure overload. J Clin Invest 2002; 109: 373-381.
122. Haq S, Choukroun G, Kang ZB, et al. Glycogen synthase kinase-3beta is a negative regulator of cardiomyocyte hypertrophy. J Cell Biol 2000; 151: 117-130.
123. Hardt SE, Sadoshima J. Glycogen synthase kinase-3beta: a novel regulator of cardiac hypertrophy and development. Circ Res 2002; 90: 1055-1063.
124. Morisco C, Seta K, Hardt SE, Lee Y, Vatner SF, Sadoshima J. Glycogen synthase kinase 3beta regulates GATA4 in cardiac myocytes. J Biol Chem 2001; 276: 28586-28597.
125. Michael A, Haq S, Chen X, et al. Glycogen synthase kinase-3beta regulates growth, calcium homeostasis, and diastolic function in the heart. J Biol Chem 2004; 279: 21383-21393.
126. Sanbe A, Gulick J, Hanks MC, Liang Q, Osinska H, Robbins J. Reengineering inducible cardiac-specific transgenesis with an attenuated myosin heavy chain promoter. Circ Res 2003; 92: 609-616.
127. Cohen P, Frame S. The renaissance of GSK3. Nat Rev Mol Cell Biol 2001; 2: 769-776.
128. Haq S, Michael A, Andreucci M, et al. Stabilization of betacatenin by a Wnt-independent mechanism regulates cardiomyocyte growth. Proc Natl Acad Sci USA 2003; 100: 4610-4615.
129. Vega RB, Yang J, Rothermel BA, Bassel-Duby R, Williams RS. Multiple domains of MCIP1 contribute to inhibition of calcineurin activity. J Biol Chem 2002; 277: 30401-30407.
130. Brancaccio M, Fratta L, Notte A, et al. Melusin, a muscle-specific integrin beta1-interacting protein, is required to prevent cardiac failure in response to chronic pressure overload. Nat Med 2003; 9: 68-75.
131. De Acetis M, Notte A, Accornero F, et al. Cardiac overexpression of melusin protects from dilated cardiomyopathy due to longstanding pressure overload. Circ Res 2005; 96: 1087-1094.
132. Ni YG, Berenji K, Dey A, et al.: Foxo Transcription Factors are Negative Modulators of Cardiac Hypertrophy: 2nd Annual Symposium of the American Heart Association Council on Basic Cardiovascular Sciences. Keystone, CO, Circ Res, 2005, vol 97, e11.
133. Skurk C, Izumiya Y, Maatz H, et al. The FOXO3a transcription factor regulates cardiac myocyte size downstream of AKT signaling. J Biol Chem 2005; 280: 20814-20823.
134. Sandri M, Sandri C, Gilbert A, et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 2004; 117: 399-412.
135. Olson, E.N.: US20020100069A1 (2002).
136. McKinsey TA, Olson EN. Toward transcriptional therapies for the failing heart: chemical screens to modulate genes. J Clin Invest 2005; 115: 538-546.
137. McKinsey TA, Zhang CL, Olson EN. MEF2: a calciumdependent regulator of cell division, differentiation and death. Trends Biochem Sci 2002; 27: 40-47.
138. Akazawa H, Komuro I. Roles of cardiac transcription factors in cardiac hypertrophy. Circ Res 2003; 92: 1079-1088.
139. Czubryt MP, Olson EN. Balancing contractility and energy production: the role of myocyte enhancer factor 2 (MEF2) in cardiac hypertrophy. Recent Prog Horm Res 2004; 59: 105-124.
140. Naya FJ, Black BL, Wu H, et al. Mitochondrial deficiency and cardiac sudden death in mice lacking the MEF2A transcription factor. Nat Med 2002; 8: 1303-1309.
141. Youn HD, Chatila TA, Liu JO. Integration of calcineurin and MEF2 signals by the coactivator p300 during T-cell apoptosis. Embo J 2000; 19: 4323-4331.
142. Bristow, M.R., Long, C., McKinsey, T.A., Olson, E.N.: EP1297851B1 (2005).
143. Finn, P.W., Kalvinsh, I., Loza, E., et al.: WO04076386172A2 (2004).
144. Long, C., Olson, E.N., Bristow, M.R., McKinsey, T.A.: US6706686 (2004).
145. Long, C., Olson, E.N., Bristow, M.R., McKinsey, T.A.: US20040186049A1 (2004).
146. McKinsey TA, Zhang CL, Olson EN. Signaling chromatin to make muscle. Curr Opin Cell Biol 2002; 14: 763-772.
147. Olson, E.N., Lu, J., McKinsey, T.A.: WO0114581C2 (2002).
148. Olson, E.N., McKinsey, T.A., Bristow, M.R., Long, C.: JP2003238445A2 (2003).
149. Zhang CL, McKinsey TA, Olson EN. Association of class II histone deacetylases with heterochromatin protein 1: potential role for histone methylation in control of muscle differentiation. Mol Cell Biol 2002; 22: 7302-7312.
150. McKinsey TA, Zhang CL, Olson EN. Activation of the myocyte enhancer factor-2 transcription factor by calcium/calmodulindependent protein kinase-stimulated binding of 14-3-3 to histone deacetylase 5. Proc Natl Acad Sci USA 2000; 97: 14400-14405.
151. Passier R, Zeng H, Frey N, et al. CaM kinase signaling induces cardiac hypertrophy and activates the MEF2 transcription factor in vivo. J Clin Invest 2000; 105: 1395-1406.
152. 2+/calmodulin-dependent protein kinase II induces hypertrophy and dilated cardiomyopathy associated with increased protein phosphatase 2A activity. J Biol Chem 2002; 277: 1261-1267.
153. McKinsey TA, Olson EN. Cardiac histone acetylation-therapeutic opportunities abound. Trends Genet 2004; 20: 206-213.
154. Chang S, McKinsey TA, Zhang CL, Richardson JA, Hill JA, Olson EN. Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol Cell Biol 2004; 24: 8467-8476.
155. Zhang CL, McKinsey TA, Chang S, Antos CL, Hill JA, Olson EN. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 2002; 110: 479-488.
156. Vega RB, Harrison BC, Meadows E, et al. Protein kinases C and D mediate agonist-dependent cardiac hypertrophy through nuclear export of histone deacetylase 5. Mol Cell Biol 2004; 24: 8374-8385.
157. McKinsey TA, Olson EN, Vega RB. WO04112763A2. (2004).
158. McKinsey TA, Zhang CL, Lu J, Olson EN. Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation. Nature 2000; 408: 106-111.
159. Jamora C, Yamanouye N, Van Lint J, et al. Gβ-mediated regulation of Golgi organization is through the direct activation of protein kinase D. Cell 1999; 98: 59-68.
160. Antos CL, McKinsey TA, Dreitz M, et al. Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors. J Biol Chem 2003; 278: 28930-28937.
161. McKinsey TA, Olson EN. Dual roles of histone deacetylases in the control of cardiac growth. Novartis Found Symp 2004; 259: 132-141; discussion 141-135, 163-139.
162. Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci USA 2003; 100: 4389-4394.
163. Hu E, Dul E, Sung CM, et al. Identification of novel isoformselective inhibitors within class I histone deacetylases. J Pharmacol Exp Ther 2003; 307: 720-728.
164. Li, Y., Ruben, S.M.: US6887683: (2005).
165. Rockman HA, Koch WJ, Lefkowitz RJ. Seven-transmembranespanning receptors and heart function. Nature 2002; 415: 206-212.
166. Koch WJ, Lefkowitz RJ, Rockman HA. Functional consequences of altering myocardial adrenergic receptor signaling. Annu Rev Physiol 2000; 62: 237-260.
167. Adams JW, Sakata Y, Davis MG, et al. Enhanced Galphaq signaling: a common pathway mediates cardiac hypertrophy and apoptotic heart failure. Proc Natl Acad Sci USA 1998; 95: 10140-10145.
168. Akhter SA, Luttrell LM, Rockman HA, Iaccarino G, Lefkowitz RJ, Koch WJ. Targeting the receptor-Gq interface to inhibit in vivo pressure overload myocardial hypertrophy. Science 1998; 280: 574-577.
169. Wettschureck N, Rutten H, Zywietz A, et al. Absence of pressure overload induced myocardial hypertrophy after conditional inactivation of Galphaq/Galpha11 in cardiomyocytes. Nat Med 2001; 7: 1236-1240.
170. D'Angelo DD, Sakata Y, Lorenz JN, et al. Transgenic Galphaq overexpression induces cardiac contractile failure in mice. Proc Natl Acad Sci USA 1997; 94: 8121-8126.
171. Esposito G, Rapacciuolo A, Naga Prasad SV, et al. Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation 2002; 105: 85-92.
172. Mochly-Rosen D, Khaner H, Lopez J, Smith BL. Intracellular receptors for activated protein kinase C. Identification of a binding site for the enzyme. J Biol Chem 1991; 266: 14866-14868.
173. Braz JC, Bueno OF, De Windt LJ, Molkentin JD. PKC alpha regulates the hypertrophic growth of cardiomyocytes through extracellular signal-regulated kinase1/2 (ERK1/2). J Cell Biol 2002; 156: 905-919.
174. Hahn HS, Marreez Y, Odley A, et al. Protein kinase Calpha negatively regulates systolic and diastolic function in pathological hypertrophy. Circ Res 2003; 93: 1111-1119.
175. Braz JC, Gregory K, Pathak A, et al. PKC-alpha regulates cardiac contractility and propensity toward heart failure. Nat Med 2004; 10: 248-254.
176. Arya R, Kedar V, Hwang JR, et al. Muscle ring finger protein-1 inhibits PKC{epsilon} activation and prevents cardiomyocyte hypertrophy. J Cell Biol 2004; 167: 1147-1159.
177. Wu G, Toyokawa T, Hahn H, Dorn GW, 2nd. Epsilon protein kinase C in pathological myocardial hypertrophy. Analysis by combined transgenic expression of translocation modifiers and Galphaq. J Biol Chem 2000; 275: 29927-29930.
178. Heidkamp MC, Bayer AL, Scully BT, Eble DM, Samarel AM. Activation of focal adhesion kinase by protein kinase C epsilon in neonatal rat ventricular myocytes. Am J Physiol Heart Circ Physiol 2003; 285: H1684-1696.
179. Eble DM, Strait JB, Govindarajan G, Lou J, Byron KL, Samarel AM. Endothelin-induced cardiac myocyte hypertrophy: role for focal adhesion kinase. Am J Physiol Heart Circ Physiol 2000; 278: H1695-1707.
180. Taylor JM, Rovin JD, Parsons JT. A role for focal adhesion kinase in phenylephrine-induced hypertrophy of rat ventricular cardiomyocytes. J Biol Chem 2000; 275: 19250-19257.
181. Iwata M, Maturana A, Hoshijima M, et al. PKC epsilon-PKD1 signaling complex at Z-discs plays a pivotal role in the cardiac hypertrophy induced by G-protein coupling receptor agonists. Biochem Biophys Res Commun 2005; 327: 1105-1113.
182. Oudit GY, Sun H, Kerfant BG, Crackower MA, Penninger JM, Backx PH. The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. J Mol Cell Cardiol 2004; 37: 449-471.
183. Patrucco E, Notte A, Barberis L, et al. PI3Kγmodulates the cardiac response to chronic pressure overload by distinct kinasedependent and-independent effects. Cell 2004; 118: 375-387.
184. Clerk A, Sugden PH. Small guanine nucleotide-binding proteins and myocardial hypertrophy. Circ Res 2000; 86: 1019-1023.
185. Fuller SJ, Gillespie-Brown J, Sugden PH. Oncogenic src, raf, and ras stimulate a hypertrophic pattern of gene expression and increase cell size in neonatal rat ventricular myocytes. J Biol Chem 1998; 273: 18146-18152.
186. Hunter JJ, Tanaka N, Rockman HA, Ross J Jr., Chien KR. Ventricular expression of a MLC-2v-ras fusion gene induces cardiac hypertrophy and selective diastolic dysfunction in transgenic mice. J Biol Chem 1995; 270: 23173-23178.
187. Thorburn A. Ras activity is required for phenylephrine-induced activation of mitogen-activated protein kinase in cardiac muscle cells. Biochem Biophys Res Commun 1994; 205: 1417-1422.
188. Bamford, M.J., Dean, D.K., Naylor, A., Takle, A.K., Wilson, D.M.: US20040209883A1 (2004).
189. Dean, D.K., Naylor, A., Takle, A.K., Wilson, D.M.: WO03022833A1 (2003).
190. Dean, D.K., Takle, A.K., Wilson, D.M.: US20040038964A1 (2004).
191. Dean, D.K., Takle, A.K., Wilson, D.M.: WO03022838A1 (2003).
192. Harris IS, Zhang S, Treskov I, Kovacs A, Weinheimer C, Muslin AJ. Raf-1 kinase is required for cardiac hypertrophy and cardiomyocyte survival in response to pressure overload. Circulation 2004; 110: 718-723.
193. Kawai M, Kawashima S, Sakoda T, et al. Ral GDP dissociation stimulator and Ral GTPase are involved in myocardial hypertrophy. Hypertension 2003; 41: 956-962.
194. Ichida M, Finkel T. Ras regulates NFAT3 activity in cardiac myocytes. J Biol Chem 2001; 276: 3524-3530.
195. Proud CG. The multifaceted role of mTOR in cellular stress responses. DNA Repair (Amst) 2004; 3: 927-934.
196. Ramirez MT, Sah VP, Zhao XL, Hunter JJ, Chien KR, Brown JH. The MEKK-JNK pathway is stimulated by alpha1-adrenergic receptor and ras activation and is associated with in vitro and in vivo cardiac hypertrophy. J Biol Chem 1997; 272: 14057-14061.
197. Wang L, Proud CG. Ras/Erk signaling is essential for activation of protein synthesis by Gq protein-coupled receptor agonists in adult cardiomyocytes. Circ Res 2002; 91: 821-829.
198. Sano M, Abdellatif M, Oh H, et al. Activation and function of cyclin T-Cdk9 (positive transcription elongation factor-b) in cardiac muscle-cell hypertrophy. Nat Med 2002; 8: 1310-1317.
199. Sano M, Schneider MD. Cyclin-dependent kinase-9: an RNAPII kinase at the nexus of cardiac growth and death cascades. Circ Res 2004; 95: 867-876.
200. Abdellatif M, Packer SE, Michael LH, Zhang D, Charng MJ, Schneider MD. A Ras-dependent pathway regulates RNA polymerase II phosphorylation in cardiac myocytes: implications for cardiac hypertrophy. Mol Cell Biol 1998; 18: 6729-6736.
201. Sano M, Schneider MD. Still stressed out but doing fine: normalization of wall stress is superfluous to maintaining cardiac function in chronic pressure overload. Circulation 2002; 105: 8-10.
202. Schneider, M.D., Sano, M.: US20040106647A1 (2004).
203. Schneider, M.D., Sano, M.: WO05027902A1 (2005).
204. Hoshijima M, Sah VP, Wang Y, Chien KR, Brown JH. The low molecular weight GTPase Rho regulates myofibril formation and organization in neonatal rat ventricular myocytes. Involvement of Rho kinase. J Biol Chem 1998; 273: 7725-7730.
205. Charron F, Tsimiklis G, Arcand M, et al. Tissue-specific GATA factors are transcriptional effectors of the small GTPase RhoA. Genes Dev 2001; 15: 2702-2719.
206. Sugden PH, Clerk A. Activation of the small GTP-binding protein Ras in the heart by hypertrophic agonists. Trends Cardiovasc Med 2000; 10: 1-8.
207. Dole, W.P., Light, D.R., Martin-McNulty, B., Schirm, S., Wang, Y.-X.: US20050014783A1 (2005).
208. Dole, W.P., Light, D.R., Martin-McNulty, B., Wang, Y.-X.: WO04105757A2 (2004).
209. Kuwahara K, Saito Y, Nakagawa O, et al. The effects of the selective ROCK inhibitor, Y27632, on ET-1-induced hypertrophic response in neonatal rat cardiac myocytes--possible involvement of Rho/ROCK pathway in cardiac muscle cell hypertrophy. FEBS Lett 1999; 452: 314-318.
210. Sah VP, Hoshijima M, Chien KR, Brown JH. Rho is required for Galphaq and alpha1-adrenergic receptor signaling in cardiomyocytes. Dissociation of Ras and Rho pathways. J Biol Chem 1996; 271: 31185-31190.
211. Wang YX, da Cunha V, Martin-McNulty B, et al. Inhibition of Rho-kinase by fasudil attenuated angiotensin II-induced cardiac hypertrophy in apolipoprotein E deficient mice. Eur J Pharmacol 2005; 512: 215-222.
212. Pracyk JB, Tanaka K, Hegland DD, et al. A requirement for the rac1 GTPase in the signal transduction pathway leading to cardiac myocyte hypertrophy. J Clin Invest 1998; 102: 929-937.
213. Sussman MA, Welch S, Walker A, et al. Altered focal adhesion regulation correlates with cardiomyopathy in mice expressing constitutively active rac1. J Clin Invest 2000; 105: 875-886.
214. Clerk A, Sugden PH. Untangling the Web: specific signaling from PKC isoforms to MAPK cascades. Circ Res 2001; 89: 847-849.
215. Wu G, Yussman MG, Barrett TJ, et al. Increased myocardial Rab GTPase expression: a consequence and cause of cardiomyopathy. Circ Res 2001; 89: 1130-1137.
216. Oi S, Haneda T, Osaki J, et al. Lovastatin prevents angiotensin IIinduced cardiac hypertrophy in cultured neonatal rat heart cells. Eur J Pharmacol 1999; 376: 139-148.
217. Luo JD, Xie F, Zhang WW, Ma XD, Guan JX, Chen X. Simvastatin inhibits noradrenaline-induced hypertrophy of cultured neonatal rat cardiomyocytes. Br J Pharmacol 2001; 132: 159-164.
218. Luo JD, Zhang WW, Zhang GP, Guan JX, Chen X. Simvastatin inhibits cardiac hypertrophy and angiotensin-converting enzyme activity in rats with aortic stenosis. Clin Exp Pharmacol Physiol 1999; 26: 903-908.
219. Dechend R, Fiebler A, Lindschau C, et al. Modulating angiotensin II-induced inflammation by HMG Co-A reductase inhibition. Am J Hypertens 2001; 14: 55S-61S.
220. Hayashidani S, Tsutsui H, Shiomi T, et al. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2002; 105: 868-873.
221. Fukuta H, Sane DC, Brucks S, Little WC. Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation 2005; 112: 357-363.
222. Bueno OF, De Windt LJ, Lim HW, et al. The dual-specificity phosphatase MKP-1 limits the cardiac hypertrophic response in vitro and in vivo. Circ Res 2001; 88: 88-96.
223. Clerk A, Pham FH, Fuller SJ, et al. Regulation of mitogenactivated protein kinases in cardiac myocytes through the small G protein Rac1. Mol Cell Biol 2001; 21: 1173-1184.
224. Heidkamp MC, Bayer AL, Martin JL, Samarel AM. Differential activation of mitogen-activated protein kinase cascades and apoptosis by protein kinase C epsilon and delta in neonatal rat ventricular myocytes. Circ Res 2001; 89: 882-890.
225. Strait JB, 3rd, Martin JL, Bayer A, Mestril R, Eble DM, Samarel AM. Role of protein kinase C-epsilon in hypertrophy of cultured neonatal rat ventricular myocytes. Am J Physiol Heart Circ Physiol 2001; 280: H756-766.
226. Clerk A, Michael A, Sugden PH. Stimulation of the p38 mitogenactivated protein kinase pathway in neonatal rat ventricular myocytes by the G protein-coupled receptor agonists, endothelin-1 and phenylephrine: a role in cardiac myocyte hypertrophy? J Cell Biol 1998; 142: 523-535.
227. Bueno OF, De Windt LJ, Tymitz KM, et al. The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. Embo J 2000; 19: 6341-6350.
228. Shibata R, Ouchi N, Ito M, et al. Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med 2004; 10: 1384-1389.
229. Dschietzig T, Bartsch C, Kinkel T, Baumann G, Stangl K. Myocardial relaxin counteracts hypertrophy in hypertensive rats. Ann N Y Acad Sci 2005; 1041: 441-443.
230. Du XJ, Samuel CS, Gao XM, Zhao L, Parry LJ, Tregear GW. Increased myocardial collagen and ventricular diastolic dysfunction in relaxin deficient mice: a gender-specific phenotype. Cardiovasc Res 2003; 57: 395-404.
231. Olson, E.N., Nicol, R.L.: CA2384907AA (2002).
232. Olson, E.N., Nicol, R.L.: US20030144176A1 (2003).
233. Olson, E.N., Rebecca, N.: JP2003055266A2 (2003).
234. Nicol RL, Frey N, Pearson G, Cobb M, Richardson J, Olson EN. Activated MEK5 induces serial assembly of sarcomeres and eccentric cardiac hypertrophy. EMBO J 2001; 20: 2757-2767.
235. Sopontammarak S, Aliharoob A, Ocampo C, Arcilla RA, Gupta MP, Gupta M. Mitogen-Activated Protein Kinases (p38 and c-Jun NH2-Terminal Kinase) Are Differentially Regulated During Cardiac Volume and Pressure Overload Hypertrophy. Cell Biochem Biophys 2005; 43: 61-76.
236. Choukroun G, Hajjar R, Kyriakis JM, Bonventre JV, Rosenzweig A, Force T. Role of the stress-activated protein kinases in endothelin-induced cardiomyocyte hypertrophy. J Clin Invest 1998; 102: 1311-1320.
237. Wang Y, Su B, Sah VP, Brown JH, Han J, Chien KR. Cardiac hypertrophy induced by mitogen-activated protein kinase kinase 7, a specific activator for c-Jun NH2-terminal kinase in ventricular muscle cells. J Biol Chem 1998; 273: 5423-5426.
238. Choukroun G, Hajjar R, Fry S, et al. Regulation of cardiac hypertrophy in vivo by the stress-activated protein kinases/c-Jun NH(2)-terminal kinases. J Clin Invest 1999; 104: 391-398.
239. Liang Q, Bueno OF, Wilkins BJ, Kuan CY, Xia Y, Molkentin JD. c-Jun N-terminal kinases (JNK) antagonize cardiac growth through cross-talk with calcineurin-NFAT signaling. Embo J 2003; 22: 5079-5089.
240. Sadoshima J, Montagne O, Wang Q, et al. The MEKK1-JNK pathway plays a protective role in pressure overload but does not mediate cardiac hypertrophy. J Clin Invest 2002; 110: 271-279.
241. Wang Y, Huang S, Sah VP, et al. Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. J Biol Chem 1998; 273: 2161-2168.
242. Zhang D, Gaussin V, Taffet GE, et al. TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice. Nat Med 2000; 6: 556-563.
243. Yang TT, Xiong Q, Enslen H, Davis RJ, Chow CW. Phosphorylation of NFATc4 by p38 mitogen-activated protein kinases. Mol Cell Biol 2002; 22: 3892-3904.
244. Baines CP, Molkentin JD. STRESS signaling pathways that modulate cardiac myocyte apoptosis. J Mol Cell Cardiol 2005; 38: 47-62.
245. Botstein, D., Goddard, A., Lawrence, D.A., Pennica, D., Roy, M.A., Wood, W.I.: US6472585 (2002).
246. Ferrara, N., King, K., Luis, E., Mather, J.P., Paoni, N.F.: US6653287 (2003).
247. Wollert KC, Chien KR. Cardiotrophin-1 and the role of gp130-dependent signaling pathways in cardiac growth and development. J Mol Med 1997; 75: 492-501.
248. Fukuzawa J, Booz GW, Hunt RA, et al. Cardiotrophin-1 increases angiotensinogen mRNA in rat cardiac myocytes through STAT3: an autocrine loop for hypertrophy. Hypertension 2000; 35: 1191-1196.
249. Kodama H, Fukuda K, Pan J, et al. Leukemia inhibitory factor, a potent cardiac hypertrophic cytokine, activates the JAK/STAT pathway in rat cardiomyocytes. Circ Res 1997; 81: 656-663.
250. Yamauchi-Takihara K, Kishimoto T. A novel role for STAT3 in cardiac remodeling. Trends Cardiovasc Med 2000; 10: 298-303.
251. Uozumi H, Hiroi Y, Zou Y, et al. gp130 plays a critical role in pressure overload-induced cardiac hypertrophy. J Biol Chem 2001; 276: 23115-23119.
252. Kunisada K, Tone E, Fujio Y, Matsui H, Yamauchi-Takihara K, Kishimoto T. Activation of gp130 transduces hypertrophic signals via STAT3 in cardiac myocytes. Circulation 1998; 98: 346-352.
253. Kunisada K, Negoro S, Tone E, et al. Signal transducer and activator of transcription 3 in the heart transduces not only a hypertrophic signal but a protective signal against doxorubicininduced cardiomyopathy. Proc Natl Acad Sci USA 2000; 97: 315-319.
254. Sano M, Fukuda K, Kodama H, et al. Interleukin-6 family of cytokines mediate angiotensin II-induced cardiac hypertrophy in rodent cardiomyocytes. J Biol Chem 2000; 275: 29717-29723.
255. Takahashi N, Saito Y, Kuwahara K, et al. Hypertrophic responses to cardiotrophin-1 are not mediated by STAT3, but via a MEK5-ERK5 pathway in cultured cardiomyocytes. J Mol Cell Cardiol 2005; 38: 185-192.
256. Banerjee A, Banks AS, Nawijn MC, Chen XP, Rothman PB. Cutting edge: Suppressor of cytokine signaling 3 inhibits activation of NFATp. J Immunol 2002; 168: 4277-4281.
257. Negoro S, Oh H, Tone E, et al. Glycoprotein 130 regulates cardiac myocyte survival in doxorubicin-induced apoptosis through phosphatidylinositol 3-kinase/Akt phosphorylation and Bcl-xL/caspase-3 interaction. Circulation 2001; 103: 555-561.
258. Hirota H, Chen J, Betz UA, et al. Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell 1999; 97: 189-198.
259. Hofmeister, A., Heinelt, U., Lang, H.-J., Bleich, M., Wirth, K., Gekle, M.: US6686384 (2004).
260. Yamazaki T, Komuro I, Kudoh S, et al. Role of ion channels and exchangers in mechanical stretch-induced cardiomyocyte hypertrophy. Circ Res 1998; 82: 430-437.
261. Takewaki S, Kuro-o M, Hiroi Y, et al. Activation of Na(+)-H+ antiporter (NHE-1) gene expression during growth, hypertrophy and proliferation of the rabbit cardiovascular system. J Mol Cell Cardiol 1995; 27: 729-742.
262. Yoshida H, Karmazyn M. Na(+)/H(+) exchange inhibition attenuates hypertrophy and heart failure in 1-wk postinfarction rat myocardium. Am J Physiol Heart Circ Physiol 2000; 278: H300-304.
263. Cingolani HE, Camilion de Hurtado MC. Na(+)-H(+) exchanger inhibition: a new antihypertrophic tool. Circ Res 2002; 90: 751-753.
264. Kusumoto K, Haist JV, Karmazyn M. Na(+)/H(+) exchange inhibition reduces hypertrophy and heart failure after myocardial infarction in rats. Am J Physiol Heart Circ Physiol 2001; 280: H738-745.
265. Engelhardt S, Hein L, Keller U, Klambt K, Lohse MJ. Inhibition of Na(+)-H(+) exchange prevents hypertrophy, fibrosis, and heart failure in beta(1)-adrenergic receptor transgenic mice. Circ Res 2002; 90: 814-819.
266. Baartscheer A, Schumacher CA, van Borren MM, et al. Chronic inhibition of Na+/H+-exchanger attenuates cardiac hypertrophy and prevents cellular remodeling in heart failure. Cardiovasc Res 2005; 65: 83-92.
267. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153.
268. Diffee GM, Seversen EA, Stein TD, Johnson JA. Microarray expression analysis of effects of exercise training: increase in atrial MLC-1 in rat ventricles. Am J Physiol Heart Circ Physiol 2003; 284: H830-837.
269. Allard MF. Energy substrate metabolism in cardiac hypertrophy. Curr Hypertens Rep 2004; 6: 430-435.
270. Goffart S, von Kleist-Retzow JC, Wiesner RJ. Regulation of mitochondrial proliferation in the heart: power-plant failure contributes to cardiac failure in hypertrophy. Cardiovasc Res 2004; 64: 198-207.
271. Matsui T, Nagoshi T, Rosenzweig A. Akt and PI 3-kinase signaling in cardiomyocyte hypertrophy and survival. Cell Cycle 2003; 2: 220-223.
272. Marcus ML, Koyanagi S, Harrison DG, Doty DB, Hiratzka LF, Eastham CL. Abnormalities in the coronary circulation that occur as a consequence of cardiac hypertrophy. Am J Med 1983; 75: 62-66.
273. Engelhardt S, Buitrago M, Lorenz K, Maass A, Schmitteckert E, Lohse MJ: The Transcriptional Repressor NAB1 is a Specific Regulator of Pathological Cardiac Hypertrophy: 2nd Annual Symposium of the American Heart Association Council on Basic Cardiovascular Sciences. Keystone, CO, Circ Res, 2005, vol 97, e9.
274. Wilkins BJ, Molkentin JD. Calcium-calcineurin signaling in the regulation of cardiac hypertrophy. Biochem Biophys Res Commun 2004; 322: 1178-1191.
275. Rothermel BA, Berenji K, Tannous P, et al. Differential Activation of Stress-Response Signaling in Load-Induced Cardiac Hypertrophy and Failure. Physiol Genomics 2005.